Debrisoquine
| |
| Names | |
|---|---|
| Preferred IUPAC name 3,4-Dihydroisoquinoline-2(1H)-carboximidamide | |
| Identifiers | |
3D model (JSmol) |
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.013.155 |
| KEGG | |
| MeSH | Debrisoquine |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C10H13N3 | |
| Molar mass | 175.23032 |
| Pharmacology | |
| C02CC04 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Debrisoquine is a derivative of guanidine. It is an antihypertensive drug similar to guanethidine. Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug-metabolizing enzyme.[2]
Debrisoquine has been identified as a inhibitor of TMPRSS2 protease, which is involved in the viral entry process of SARS-CoV-2. In a laboratory study, it showed antiviral activity by blocking the ability of the virus to enter human lung cells.[3]
The guanidine part of the molecule also appears in guanoxan and guanadrel.[citation needed] The 7-bromo analog of debrisoquine is called guanisoquin.[citation needed]
See also
References
- ^ Debrisoquine – Compound Summary, PubChem.
- ^ Fuhr, U.; Jetter, A.; Kirchheiner, J. (2007). "Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the "Cocktail" Approach". Clinical Pharmacology & Therapeutics. 81 (2): 270–283. doi:10.1038/sj.clpt.6100050. PMID 17259951.
- ^ Peiffer AL, Garlick JM, Wu Y, Wotring JW, Arora S, Harmata AS, Bochar DA, Stephenson CJ, Soellner MB, Sexton JZ, Brooks CL, Mapp AK (June 2023). "TMPRSS2 Inhibitor Discovery Facilitated through an In Silico and Biochemical Screening Platform". ACS Medicinal Chemistry Letters. 14 (6): 860–866. doi:10.1021/acsmedchemlett.3c00035. PMC 10237299. PMID 37284689.